Italian study of radioreceptor therapy for rare hormone tumors
Part of Cancer clinical trials.
This study reviews medical records of patients with pheochromocytoma or paraganglioma (rare tumors that produce hormones and can spread) who were treated with a radioactive injection therapy between 2000 and 2024. Researchers want to understand how well this treatment works and its long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pheochromocytoma or paraganglioma (a rare tumor)
- Your tumor was either impossible to remove with surgery or had spread to other parts of your body
- You received at least one treatment with radioactive peptide receptor therapy (PRRT) between January 2000 and February 2024
- Medical records are available showing your imaging scans and health updates after treatment
- You have follow-up medical information for at least 12 months after your last treatment, or records showing your disease got worse or you passed away within that time
- Your medical records can be accessed from the hospital where you were treated or through official data-sharing agreements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
Hear when a new Pheochromocytomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.